Merck & Co., Inc. (BMV:MRK)

Market Cap	4.91T
Revenue (ttm)	1.18T
Net Income (ttm)	349.13B
Shares Out	n/a
EPS (ttm)	138.59
PE Ratio	14.06
Forward PE	13.62
Dividend	61.71 (3.08%)
Ex-Dividend Date	Dec 15, 2025

Volume	6,213
Average Volume	1,827
Open	1,990.00
Previous Close	1,979.99
Day's Range	1,990.00 - 2,003.20
52-Week Range	1,425.00 - 2,097.01
Beta	0.30
RSI	57.41
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD